<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04018430</url>
  </required_header>
  <id_info>
    <org_study_id>Lmzrisch</org_study_id>
    <nct_id>NCT04018430</nct_id>
  </id_info>
  <brief_title>Impact of Oral Glucose Tolerance Test on Extent of Hemoglobin Glycation</brief_title>
  <acronym>HbA1c</acronym>
  <official_title>Impact d'Une Surcharge Glycemique Sur le Taux HbA1c</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Urs E. Nydegger</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Labormedizinisches Zentrum Dr. Risch</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Labormedizinisches Zentrum Dr. Risch</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The glycation extent of human hemoglobin is under control of the Maillard reaction, a
      chemical interaction between an amino acide and a reducing sugar. About 5% ( 31.1 mmol/mol)
      of hemoglobin molecules secluded in a red blood cell are glycated; excessive values &gt; 6.5%
      point to prediabetes or overt diabetes mellitus. To ascertain the diagnosis doctors prescribe
      oral glucose tolerance upon which glucose concentrations in blood increase - how much HbA1c
      reacts under these circumstances is ill known.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Medical laboratory assays for delineation of impaired glucose metabolism and overt diabetes
      mellitus, beyond measurement of (fasting) blood serum or plasma glucose levels, include
      extent of hemoglobin A1c glycation, concentration of fructosamines, insulin concentrations to
      calculate the homeostasis model assessment (HOMA) index and other clinically putative
      biomarkers of glucose homoeostasis. HbA1c levels form now part of routine elucidation of
      metabolic disorders and are used for therapy monitoring. Initially used to monitor glucose
      levels in follow-up care of diabetics it is considered as a track marker of ups and downs of
      blood glucose concentrations. Its behavior under the 2 h period of oral glucose tolerance
      tests (OGTT) is ill known - most clinicians believe the glycation extent will not change.
      Since the dynamics of glycation is temperature dependent,non-febrile patients under OGTT
      likely keep their glycation extent between time zero and 120 min after glucose charge
      constant but this has not been investigated and with the sensitive lab assays for HbA1c now
      in use we postulate a significant increase in glycation. The Patient Registry includes
      recruited children and adults sick from diabetes, overweight or metabolic syndrome as a
      whole. Three medical offices will address their patients to the VidyMed lab to perform the
      OGTT framed by lab assays on venous blood samples
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2019</start_date>
  <completion_date type="Anticipated">September 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2020</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>20 Days</target_duration>
  <primary_outcome>
    <measure>HbA1c concentration upon oral glucose tolerance testing</measure>
    <time_frame>48 hours</time_frame>
    <description>HbA1c significantly increases upon oral glucose tolerance testing</description>
  </primary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Blood Glucose, High</condition>
  <condition>Oral Hypoglycaemic Overdose</condition>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      venous blood samples processed to yield 4 ml of blood plasma
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        (i) Those suspected to suffer from the metabolic syndrome including high blood pressure,
        high blood sugar, excess of body fat and increased cholesterol levels (ii) patients with
        overt impaired carbohydrate metabolisms, under treatment and tested for follow up
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  apparently healthy subjects or subjects supposedly experiencing a metabolic disease
             (e.g. prediabetes) Subjects with asked for fasting blood glucose

        Exclusion Criteria:

          -  current steroid use thyroid dysfunction (free-thyroxin levels &lt; 9 or &gt; 19 pmol/L,
             hsCRP &gt; 10 mg/L hospitalized
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Urs Nydegger, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Labormedizinisches Zentrum Dr. Risch</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nathalie Gilli√©ron, CT</last_name>
    <phone>+41(0)21 622.87.32</phone>
    <email>nathalie.gillieron@vidymed.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Urs Nydegger, MD</last_name>
    <phone>+41(0)58 523.34.66</phone>
    <email>urs.nydegger@risch.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Bern</name>
      <address>
        <city>Bern</city>
        <state>Kanton Bern</state>
        <zip>3000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <reference>
    <citation>Medina Escobar P, Moser M, Risch L, Risch M, Nydegger UE, Stanga Z. Impaired glucose metabolism and type 2 diabetes in apparently healthy senior citizens. Swiss Med Wkly. 2015 Nov 23;145:w14209. doi: 10.4414/smw.2015.14209. eCollection 2015.</citation>
    <PMID>26594954</PMID>
  </reference>
  <reference>
    <citation>Rabbani N, Ashour A, Thornalley PJ. Mass spectrometric determination of early and advanced glycation in biology. Glycoconj J. 2016 Aug;33(4):553-68. doi: 10.1007/s10719-016-9709-8. Epub 2016 Jul 20. Review.</citation>
    <PMID>27438287</PMID>
  </reference>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>July 10, 2019</study_first_submitted>
  <study_first_submitted_qc>July 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 12, 2019</study_first_posted>
  <last_update_submitted>July 10, 2019</last_update_submitted>
  <last_update_submitted_qc>July 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Labormedizinisches Zentrum Dr. Risch</investigator_affiliation>
    <investigator_full_name>Urs E. Nydegger</investigator_full_name>
    <investigator_title>Head Hematology Senior Consultant</investigator_title>
  </responsible_party>
  <keyword>glucose, insulin, HbA1c</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperglycemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>peer reviewed publication in an anglophone scientific journal. No IPD sharing</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

